论文部分内容阅读
在全国药品交易会在沪举行期间,上海利生制药厂在2000年12月8日假座中亚饭店召开新闻发布会,隆重推出国家中药二类新药、上海高新技术成果、国家专利产品西红花多甙片。 由中国药科大学、上海萨福郎实业有限公司研制,上海利生制药厂生产的西红花多甙片,系采用高新技术从素有“植物黄金”之称的名贵药材西红花中提取多甙成分精制而成,它与传统中药的本质差别在于其有效成分及规定的有效剂量都可以分析测定,这是实现中药现代化的重大突破。西红花多甙片具有活血化瘀、通脉止痛的功效,用于治疗胸痹心痛(冠心病、心绞痛)患者的心血瘀阻症,疗效确切,通过祛除瘀阻、疏通脉道而明显改善冠心病、心绞痛患者的症状。Ⅱ期临床试
During the National Pharmaceutical Trade Fair in Shanghai, Shanghai Lisheng Pharmaceutical Factory held a press conference at the Central Asian Hotel on December 8th, 2000, and launched a grand launch of the national second-tier Chinese medicines, Shanghai high-tech achievements, and national patent products. Sepia. Developed by China Pharmaceutical University and Shanghai Safuro Industrial Co., Ltd., Shanghai Lee Sang Pharmaceutical Co., Ltd. manufactures a variety of safflower pods that are extracted from safflower, a valuable medicinal material known as “plant gold”. The essential component of wolfberry is refined. The essential difference between traditional Chinese medicine and traditional Chinese medicine lies in that its effective ingredients and prescribed effective dose can be analyzed and determined. This is a major breakthrough in the modernization of traditional Chinese medicine. The safflower multi-cockroaches have the effects of promoting blood circulation, relieving phlegm, and relieving pain. They are used to treat heart-blood stasis in patients with chest pain (coronary heart disease, angina pectoris). The curative effect is definite, and it is significantly improved by eliminating phlegm obstruction and clearing the vascular tract. Symptoms of coronary heart disease, angina pectoris. Phase II clinical trial